Your browser doesn't support javascript.
loading
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot, T; Ciruelos, E; Schneeweiss, A; Puglisi, F; Peretz-Yablonski, T; Bondarenko, I; Paluch-Shimon, S; Wardley, A; Merot, J-L; du Toit, Y; Easton, V; Lindegger, N; Miles, D.
Afiliação
  • Bachelot T; Medical Oncology Department, Centre Léon Bérard, Lyon, France. Electronic address: thomas.bachelot@lyon.unicancer.fr.
  • Ciruelos E; Medical Oncology Department Breast Care Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Schneeweiss A; Gynecologic Oncology Division, National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany.
  • Puglisi F; IRCCS Centro di Riferimento Oncologico Aviano-National Cancer Institute, Aviano; Department of Medicine, University of Udine, Udine, Italy.
  • Peretz-Yablonski T; Sharett Institute of Oncology and Center for Malignant Breast Diseases, Hadassah Medical Organization, Jerusalem, Israel.
  • Bondarenko I; City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine.
  • Paluch-Shimon S; Breast Oncology Unit, Shaare Zedek Medical Centre, Jerusalem, Israel.
  • Wardley A; The NIHR Manchester Clinical Research Facility at the Christie NHS Foundation Trust, Manchester; Faculty of Biology Medicine & Health, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
  • Merot JL; Medical and Scientific Services, Oncology Therapeutic Unit, IQVIA, Saint Ouen, France.
  • du Toit Y; Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Easton V; Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Lindegger N; Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Miles D; Mount Vernon Cancer Centre, Middlesex, UK.
Ann Oncol ; 30(5): 766-773, 2019 05 01.
Article em En | MEDLINE | ID: mdl-30796821
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Neoplasias da Mama Masculina / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Neoplasias da Mama Masculina / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article